AvenCell Doses First Patient With Switchable Dual-Target CAR-T
AvenCell's AVC-203 is the first CRISPR-engineered allogeneic CAR-T with a switchable receptor to hit the clinic — and the timing couldn't be better.
Category Voyager Articles
FORE Biotherapeutics Completes the FDA Hat Trick for Plixorafenib in Brain Cancer
Plixorafenib just became the first targeted therapy to earn Breakthrough Therapy Designation in high-grade glioma — adding to Fast Track and Orphan Drug status.
Senti Biosciences Publishes Gene Circuit Science Behind Logic-Gated AML Therapy
The science behind programming immune cells with Boolean logic just got peer-reviewed — and the early clinical signals in AML are turning heads.
ARPA-H Awards Landmark Bio $18.3M to Solve the EV Therapeutics Manufacturing Problem
The US government is betting that extracellular vesicle therapies are bottlenecked by manufacturing, not science. $18.3M says they're right.
Korsana Biosciences Raises $380M, Merges With Cyclerion to Chase Alzheimer’s
From stealth to $555M raised in under two years. Korsana's brain-shuttled Alzheimer's antibody just got a public shell and a war chest.
Newleos Doses First Patient in Anti-Anxiety Drug Trial Designed to Replace Benzos
A GABA-selective anxiolytic that dodges sedation and addiction? Newleos just started dosing patients in the UK.
Ray Therapeutics Lands FDA RMAT Designation for Optogenetic Vision Therapy RTx-015
A single intravitreal injection that reprograms retinal cells to detect light. The FDA just gave it the fast lane.
AviadoBio Reclaims Full Rights to FTD Gene Therapy and Pushes Into Fourth Dose Cohort
AviadoBio regained full rights to its FTD gene therapy, secured disease-foundation funding, and initiated the fourth dose cohort — all in the same announcement.
Pelthos Takes the NaV1.7 Pain Target to Your Eyes With First Patient Dosed
NaV1.7 has been the white whale of pain drug development. Pelthos just dosed the first patient with a NaV1.7 inhibitor — but instead of systemic pain, they're targeting your eyeballs.
Ernexa Therapeutics Heads Toward IND With Engineered Stem Cells That Turn Cold Tumors Hot
Ernexa's ERNA-101 uses engineered stem cells to make cold tumors respond to immunotherapy — with complete tumor regression in preclinical models and an IND filing planned for Q3.